Results 121 to 130 of about 4,313 (158)
Impact of IL-5 Pathway Inhibition on Circulating Eosinophil- and Remodeling-Related Biomarkers in Severe Eosinophilic Asthma. [PDF]
J Asthma AllergyDamiański P +4 more
europepmc +1 more source
Differential Effects of Benralizumab and Mepolizumab on Pro-Resolving Mediators. [PDF]
AllergyBernaola J +14 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Benralizumab for the treatment of asthma
Expert Review of Clinical Immunology, 2017Benralizumab is a humanized monoclonal antibody directed at the a subunit of the interleukin-5 receptor (IL-5R) that is under clinical development. The binding of benralizumab with the alpha chain of IL-5R results in inhibition of hetero-oligomerization of alpha and beta subunits and thus no signal transduction occurs.
Tara Vinyette Saco, Amber N Pepper
exaly +7 more sources
Benralizumab for eosinophilic granulomatosis with polyangiitis
Annals of the Rheumatic Diseases, 2023Benralizumab is effective in the treatment of eosinophilic asthma and is being investigated for the treatment of other eosinophil-associated diseases. Reports on the use of benralizumab for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) are limited to case reports and small case series.We conducted a multicentre, retrospective ...
Cottu, Adrien +25 more
openaire +2 more sources
Benralizumab: for asthma, not yet for COPD
The Lancet Respiratory Medicine, 2014Asthma and chronic obstructive pulmonary disease (COPD) are two distinct, chronic, inflammatory respiratory diseases.1,2 Asthma develops early in life, mainly in atopic individuals, and is characterised by airway hyper-responsiveness and recurrent wheezing due to a chronic inflammation of the airways caused by a CD4, T-helper type-2, eosinophilic ...
openaire +3 more sources